Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD‐L1 axis in gastric cancer
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867006463665242113 |
|---|---|
| author | Qi Zhang Chenying Yang Zhijian Ma Liangwen Ye Yunfeng Wu Caiyun Zhong Ye Shi Mingming Zhu |
| author_facet | Qi Zhang Chenying Yang Zhijian Ma Liangwen Ye Yunfeng Wu Caiyun Zhong Ye Shi Mingming Zhu Qi Zhang Chenying Yang Zhijian Ma Liangwen Ye Yunfeng Wu Caiyun Zhong Ye Shi Mingming Zhu |
| collection | Wiley Open Access |
| contents | Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD‐L1 axis in gastric cancer Qi Zhang Chenying Yang Zhijian Ma Liangwen Ye Yunfeng Wu Caiyun Zhong Ye Shi Mingming Zhu Molecular Carcinogenesis AbstractSulforaphane (SFN) exerts anticancer effect on various cancers including gastric cancer. However, the regulatory effect of SFN on programmed death‐ligand 1 (PD‐L1) and checkpoint blockade therapy in gastric cancer have not been elucidated. Here we demonstrated that SFN suppressed gastric cancer cell growth both in vitro and in vivo study. SFN upregulated PD‐L1 expression through activating ΔNP63α in gastric cancer cells. Further, we found that SFN impaired the anticancer effect of anti‐PD‐L1 monoclonal antibody (α‐PD‐L1 mab) on gastric cancer cells. These results uncover a novel PD‐L1 regulatory mechanism and the double‐edged role of SFN in gastric cancer intervention. 10.1002/mc.23749 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/mc.23749 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_mc_23749 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD‐L1 axis in gastric cancer Qi Zhang Chenying Yang Zhijian Ma Liangwen Ye Yunfeng Wu Caiyun Zhong Ye Shi Mingming Zhu Molecular Carcinogenesis Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD‐L1 axis in gastric cancer Qi Zhang Chenying Yang Zhijian Ma Liangwen Ye Yunfeng Wu Caiyun Zhong Ye Shi Mingming Zhu Molecular Carcinogenesis AbstractSulforaphane (SFN) exerts anticancer effect on various cancers including gastric cancer. However, the regulatory effect of SFN on programmed death‐ligand 1 (PD‐L1) and checkpoint blockade therapy in gastric cancer have not been elucidated. Here we demonstrated that SFN suppressed gastric cancer cell growth both in vitro and in vivo study. SFN upregulated PD‐L1 expression through activating ΔNP63α in gastric cancer cells. Further, we found that SFN impaired the anticancer effect of anti‐PD‐L1 monoclonal antibody (α‐PD‐L1 mab) on gastric cancer cells. These results uncover a novel PD‐L1 regulatory mechanism and the double‐edged role of SFN in gastric cancer intervention. 10.1002/mc.23749 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD‐L1 axis in gastric cancer |
| topic | Molecular Carcinogenesis |
| url | https://onlinelibrary.wiley.com/doi/10.1002/mc.23749 |